Oxford Biomedica (LON:OXB) Stock Price Down 5.1% – Here’s What Happened

Oxford Biomedica plc (LON:OXB) shares fell 5.1% during mid-day trading on Wednesday . The company traded as low as GBX 424 and last traded at GBX 424. 2,402,807 shares were traded during trading, an increase of 122% from the average daily volume of 1,081,424 shares. The stock had previously closed at GBX 447.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday. Royal Bank Of Canada restated an “outperform” rating and set a GBX 900 price objective on shares of Oxford Biomedica in a research report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Oxford Biomedica has an average rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Price Performance

The stock has a market capitalization of £513.20 million, a P/E ratio of -15.75 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. The firm has a 50-day moving average price of GBX 566.92 and a 200 day moving average price of GBX 606.44.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.